A breakthrough in treating blindness: AI helps scientists grow artificial retinal tissue

Researchers have developed a new AI model that could be a game-changer in the treatment of blindness and vision loss, sharing their findings in Frontiers in Cellular Neuroscience.

The team found that convolutional neural networks (CNNs) can be trained to recognize, differentiate and predict retinal tissues during the process of tissue differentiation in stem cell-derived organoids. This could help scientists grow retinal tissue, a key step in developing new drugs and treatments focused on cell replacement.

“The human retina has a very limited capacity for regeneration,” study co-author Pavel Volchkov, a geneticist at the Moscow Institute of Physics and Technology, said in a statement. “This means that any progressive loss of neurons—for example, in glaucoma—inevitably leads to complete loss of vision. And there is nothing a physician can recommend, short of getting a head start on learning Braille. Our research takes biomedicine a step closer to creating a cellular therapy for retinal diseases that would not only halt the progression but reverse vision loss.”

The CNN was trained on 750 images, with 400 additional images being set aside for validation and testing, and its final accuracy was 84%.

There is potential, the specialists wrote, that this breakthrough could lead to the growth of other human artificial organs as well.

The full Frontiers in Cellular Neuroscience study is available here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The ACC, AHA, HFSA, HRS and SCAI all worked together to try and make the new board a reality. Though their proposal has been denied, the groups say they are not done fighting. 

The Outsourcing Facilities Association, a Texas-based trade group, is alleging that supply issues still remain for Ozempic and Wegovy. The group believes the FDA has ignored those issues.

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement.